What is the recommended dosing regimen for eptifibatide (Integrilin), including adjustments for impaired renal function?

Eptifibatide (Integrilin) Dosing

For patients undergoing PCI or with acute coronary syndromes, administer eptifibatide as a double bolus of 180 mcg/kg IV given 10 minutes apart, followed by a continuous infusion of 2.0 mcg/kg/min; reduce the infusion rate by 50% to 1.0 mcg/kg/min in patients with creatinine clearance <50 mL/min. 1, 2, 3, 4, 5

Standard Dosing Regimen

For PCI and ACS (UA/NSTEMI/STEMI)

Loading Dose:

• 180 mcg/kg IV bolus followed 10 minutes later by a second 180 mcg/kg IV bolus 1, 2, 3, 4, 5
• This double-bolus regimen is critical for achieving rapid and adequate platelet inhibition 2, 3, 2

Maintenance Infusion:

• 2.0 mcg/kg/min continuous infusion, started after the first bolus 1, 2, 3, 4, 5
• Continue infusion for 12 to 18 hours at physician discretion 1, 2, 3, 4

Renal Dose Adjustments

The creatinine clearance threshold of 50 mL/min is the critical decision point for dose adjustment 1, 2, 3, 4, 5, 6, 7:

Moderate Renal Impairment (CrCl <50 mL/min but ≥30 mL/min):

• Bolus dose remains unchanged: 180 mcg/kg IV × 2 doses 1, 6, 7
• Reduce infusion by 50%: 1.0 mcg/kg/min 1, 2, 3, 4, 5, 6
• This adjustment is based on pharmacokinetic data showing approximately 50% reduction in eptifibatide clearance with renal impairment 7

Severe Renal Impairment (CrCl <30 mL/min):

• Eptifibatide is contraindicated 6, 8
• Approximately 50% of eptifibatide is cleared renally, leading to drug accumulation and significantly increased bleeding risk 9, 7

Normal or Mild Renal Impairment (CrCl >50 mL/min):

• Use standard dosing without adjustment 1, 2, 3, 4, 5

Critical Implementation Points

Calculate creatinine clearance for ALL patients before initiating eptifibatide—serum creatinine alone is inadequate for dosing decisions 10, 7, 11. Use the Cockcroft-Gault equation or institutional equivalent.

Common dosing errors to avoid:

• Studies show that 34-45% of patients with CrCl <50 mL/min receive inappropriate (excessive) dosing 12, 13, 11
• Failure to adjust the infusion rate in renal impairment significantly increases bleeding risk, with up to 20% bleeding rates reported with inappropriate dosing 11
• The bolus dose should NOT be adjusted—only the maintenance infusion requires modification 7

Age considerations: Increased age is the strongest independent predictor of bleeding with eptifibatide 11. This relationship appears largely mediated through age-related decline in renal function, reinforcing the importance of calculating CrCl rather than relying on age or creatinine alone 11.

Clinical Context

When to use eptifibatide:

• Class I recommendation (Level of Evidence A) for patients undergoing PCI who have NOT received prior P2Y12 inhibitor therapy 1, 4, 5
• Of uncertain benefit in patients already receiving P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) 1, 4, 5
• Can be used in medical management of UA/NSTEMI when there is appreciable delay to angiography/PCI 1

Monitoring requirements:

• Platelet count should be monitored for thrombocytopenia (occurs in <1% of patients) 9, 14
• Severe thrombocytopenia (<20,000/μL) is rare (0.2%) but immune-mediated 9
• Activated clotting time (ACT) monitoring during PCI as per institutional protocols

Drug interactions:

• Increased bleeding risk when combined with other antiplatelet agents, anticoagulants, or thrombolytics 15
• All patients should receive aspirin 162-325 mg 1, 2, 3, 4